Stage III &amp; IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry

Gawlick, Ute; Lu, Kim C.; Douthit, Miriam A.; Diggs, Brian S.; Schuff, Kathryn G.; Herzig, Daniel O.; Tsikitis, Vassiliki L.

doi:10.1016/j.amjsurg.2013.01.029

Cited by 9 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A more recent study also confirmed that advanced stage III and IV colon and rectal cancers share similar molecular profiles, with the exception, as previously reported, of BRAF mutations which are more frequent in colon cancer compared with rectal cancer (Gawlick et al, 2013). An exploratory analysis of clinical correlations by genotype in patients with metastatic colon and rectal cancer also confirmed the prevalence of BRAF mutation in colon cancer but, in addition it also showed for the first time a significant increase in NRAS mutation rate in older patients with rectal cancer; such finding needs to be further investigated (Russo et al, 2014).…”

Section: Q2supporting

confidence: 82%

A perspective on the current treatment strategies for locally advanced rectal cancer

Avallone

Aloj

Aprile

et al. 2015

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

Section: Q2supporting

confidence: 82%

A perspective on the current treatment strategies for locally advanced rectal cancer

Avallone

Aloj

Aprile

et al. 2015

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

“…17,18 Other studies have shown similar molecular profiles between colon and rectum except for the BRAF mutation frequency. 19 A large study of 1443 colorectal cancers found that there is a gradual shift in molecular characteristics along the length of the bowel, particularly in relationship to the frequency of BRAF mutations, microsatellite instability-high status, and CpG island methylator phenotype (CIMP)-high tumors. 20 The TCGA analysis found no difference between colon and rectal carcinomas in copy number, CIMP, messenger RNA, and microRNA in nonhypermutated tumors.…”

Section: Resultsmentioning

confidence: 99%

Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas

Crumley

Pepper

Phan

et al. 2015

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

-The somatic mutations identified in our rectal adenocarcinoma cohort showed a strong correlation to those previously characterized in colonic adenocarcinoma. In addition, most rectal adenocarcinomas harbored identical somatic mutations in both the primary tumor and metastasis. These findings demonstrate evidence that rectal adenocarcinoma follows a similar molecular pathogenesis as colonic adenocarcinoma and that sampling either the primary or metastatic lesion is valid for initial evaluation of somatic mutations and selection of possible targeted therapy.

show abstract

“…Efforts have been made to classify risk with morphological and histological criteria with better patients' selection (1,(6)(7)(8)(9); however, the risk stratification remains imperfect. Molecular biomarkers have been used in prognosis of colorectal cancer (CRC) in general and rectal cancer seems to follow the same genetic phenotype (19). So far, data in the literature, that link biomarkers and oncologic outcomes from TEMS, are limited.…”

mentioning

confidence: 99%

KRAS Mutant Status, p16 and β-catenin Expression May Predict Local Recurrence in Patients Who Underwent Transanal Endoscopic Microsurgery (TEMS) for Stage I Rectal Cancer

Sideris

Moorhead

Díaz‐Cano

et al. 2016

View full text Add to dashboard Cite

Abstract. Background The method of local excision, that has recently, gained wider acceptance, in early rectal cancer, is transanal endoscopic microsurgery (TEMS). TEMS generally offers advantages in operative access and oncological clearance over transanal resection (TAR), but recently a number of similar logic techniques with various rectal ports for endoscopic excision of rectal tumours has been invented. Those methods are collectively named transanal minimal-invasive surgery (TAMIS) and for oncological purposes they share the same features of local excision as TEMS (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14).TEMS is a minimally invasive technique that was introduced by Buess in the early 1980's (2). Through the new rectoscope with 3D binocular optic and the endoscopic instruments, it offers better access to proximal lesions with lower margin positivity and fragmentation and magnification of the operative field (2, 15). TEMS is a safe procedure that offers low complication rates and peri-operative morbidity (10.7%) (4). There have been multiple studies to suggest that TEMS is the operation of choice for rectal adenomas (1), retrorectal and submucosal rectal lesions (5). Furthermore, TEMS offers the advantage of not damaging the anorectal function (7).TEMS is indicated as a curative treatment for malignant neoplasms that are histologically confirmed as pT1 sm1 carcinomas, whereas T1 sm2-3 and T2 lesions are still under question (8). A number of studies have shown that TEMS can have comparable results with radical surgery (1,8,12,16) for rectal cancer.There has been concern about oncologic outcomes following TEMS (17). Some studies support that there is potentially a higher risk of local recurrence rate with TEMS (8,10,18). Efforts have been made to classify risk with morphological and histological criteria with better patients' selection (1, 6-9); however, the risk stratification remains 5315

show abstract

Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry

Cited by 9 publications

References 19 publications

A perspective on the current treatment strategies for locally advanced rectal cancer

A perspective on the current treatment strategies for locally advanced rectal cancer

Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas

KRAS Mutant Status, p16 and β-catenin Expression May Predict Local Recurrence in Patients Who Underwent Transanal Endoscopic Microsurgery (TEMS) for Stage I Rectal Cancer

Contact Info

Product

Resources

About